Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with traumatic brain injury admitted to the hospital less than 24 hours prior to randomization~* GCS score 3-8 (inclusive) or GCS motor score of 5 or less and abnormal admission CT scan showing intracranial pathology~* Hemodynamically stable with a systolic BP \> 90 mmHg~* At least one reactive pupil~* Age at least 18 years~* Signed informed consent and HIPAA authorization for research form~* Patients will not be excluded because of race, gender, educational status or occupation~Exclusion Criteria:~* No venous access~* Spinal cord injury~* History of or CT confirmation of previous brain injury such as brain tumor, cerebral infarct, or spontaneous intracerebral hemorrhage~* Hemodynamically unstable~* Suspected anoxic events~* Other peripheral trauma likely to result in liver failure~* Age less than 18 years of age~* Known hypersensitivity to any anticonvulsant~* Any treatment, condition, or injury that contraindicates treatment with Lacosamide (LCM) or fos-phenytoin (fPHT)~* Inability to obtain signed informed consent or HIPAA authorization for research

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV LCM (lacosamide) (Type: EXPERIMENTAL): Patients with severe traumatic brain injury (TBI) or subarachanoid hemorrhage (SAH) randomized to seizure prophylaxis with either lacosamide.
- IV fPHT (fos-phenytoin) (Type: ACTIVE_COMPARATOR): Patients with TBI or SAH randomized to seizure prophylaxis with fos-phenytoin

Based on this trial design, predict the completion outcome and termination type (if applicable).